July
PhRMA names board nominees
Pharmaceutical Research and Manufacturers of America has nominated four industry figures to serve on a new comparative effectiveness board
01 Jul 2010
Biogen Idec appoints new CEO
Biogen Idec has appointed George A Scangos, a veteran of Elelixis and Bayer, as the company's new CEO and a member of the board of directors
01 Jul 2010
Afinitor extends pancreatic cancer survival
Results of a phase III trial show Novartis' Afinitor more than doubled progression-free survival in patients with advanced pancreatic tumours
01 Jul 2010
S-A's rifapentine granted Orphan Drug status
Sanofi-Aventis' tuberculosis drug, rifapentine, has been granted Orphan Drug status by the European Commission
01 Jul 2010
Eisai/ Arena agreement for lorcaserin
Eisai Inc has entered into an agreement with Arena Pharmaceuticals for the rights to commercialise obesity drug candidate, lorcaserin
01 Jul 2010
GSK sells Italian research unit to Aptuit
GSK is to sell its Medicines Research Centre in Verona, Italy to Aptuit Inc who will continue to employ all 500 staff who work at the centre
01 Jul 2010
AZ and MRCT serious diseases collaboration
AstraZeneca and MRC Technology have announced a new strategic collaboration to advance promising compounds for serious diseases
05 Jul 2010
Sanofi-aventis looking at $20bn acquisition
Sanofi-aventis may be planning a US acquisition worth over $20bn with speculation focused on a US-based biotech company
05 Jul 2010
Novartis disappointed by NICE ruling
Novartis Oncology strongly disagrees with the NICE decision to deny advanced kidney cancer patients in the UK access to Afinitor
05 Jul 2010
EMA conditional approval for Votrient
GSK's Votrient is available for first-line treatment of advanced RCC, and for patients who have previously received cytokine therapy
05 Jul 2010